Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefitClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients